Special Investigation Of Xalkori For Nsclc (Regulatory Post Marketing Commitment Plan)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 20 Nov 2017 Planned End Date changed from 31 Jan 2018 to 1 Jan 2018.
- 20 Nov 2017 Planned primary completion date changed from 31 Jan 2018 to 1 Jan 2018.
- 12 Sep 2017 Status changed from completed to active, no longer recruiting.